KRAS mutations constitute the most prevalent driver mutation in EGFR-negative LUAD, notably with the smoking-associated KRAS G12C subtype predominating, accounting for around 13% of all NSCLC cases. Here, KRAS is linked to non-small cell lung carcinoma.